On December 22, Novo Nordisk announced that the cardiovascular application for the weight reduction version of simeglutide injection has been approved in China to reduce the risk of major adverse cardiovascular events in adult patients diagnosed with cardiovascular disease and a BMI greater than 27. According to the company, as one of the important methods in the current standardized treatment of obesity, the weight loss version of simeglutide injection can reduce the weight of about one-third of patients by more than 20%, and can reduce the risk of major adverse cardiovascular events by 20%. It is the only weight loss drug that has been proven to reduce both weight loss and the risk of major adverse cardiovascular events.

On December 22, Novo Nordisk announced that the cardiovascular application for the weight reduction version of simeglutide injection has been approved in China to reduce the risk of major adverse cardiovascular events in adult patients diagnosed with cardiovascular disease and a BMI greater than 27. According to the company, as one of the important methods in the current standardized treatment of obesity, the weight loss version of simeglutide injection can reduce the weight of about one-third of patients by more than 20%, and can reduce the risk of major adverse cardiovascular events by 20%. It is the only weight loss drug that has been proven to reduce both weight loss and the risk of major adverse cardiovascular events.